Compugen (CGEN) grants CFO 26,000 options and 19,500 RSUs

Rhea-AI Filing Summary

Compugen Ltd granted Chief Financial Officer David Silberman 19,500 restricted stock units and 26,000 share options on July 29, 2026. The options have an exercise price of 2.2600 and expire on July 29, 2036. Both awards vest 25% on September 30, 2027, with the remainder in 12 equal quarterly installments, subject to continued service. Following the RSU grant, Silberman directly holds 55,000 ordinary shares and 26,000 options.

Insider Trade Summary

Net Buyer: 19,500 shares

Net Buy 2 txns

Insider Silberman David

Role Chief Financial Officer

Type	Security	Shares	Price	Value
Grant/Award	Share Option (right to buy) F2	26,000	$0.00	$0.00
Grant/Award	Ordinary Shares F1	19,500	$0.00	$0.00

Holdings After Transaction: Share Option (right to buy) — 26,000 shares (Direct); Ordinary Shares — 55,000 shares (Direct)

Footnotes (2)

1. F1. Represents a restricted stock unit ("RSU") award. The RSUs vest 25% on September 30, 2027, and the remainder vests in 12 equal quarterly installments thereafter, subject to the Reporting Person's continued service to the Issuer.
2. F2. This option vests 25% on September 30, 2027 and the remainder vests in 12 equal quarterly installments thereafter, subject to the Reporting Person's continued service to the Issuer.

Key Figures

Share options granted: 26000.0000 Option exercise price: 2.2600 Option expiration date: 2036-07-29 +4 more

7 metrics

Share options granted 26000.0000 Share Option (right to buy) granted to CFO on 2026-07-29

Option exercise price 2.2600 Exercise price per share for options granted on 2026-07-29

Option expiration date 2036-07-29 Expiration date of CFO share options

RSUs granted 19500.0000 Restricted stock unit award granted on 2026-07-29

Initial vesting date 2027-09-30 25% of both RSUs and options vest on this date

Ordinary shares after grant 55000.0000 Total ordinary shares directly held by CFO after RSU grant

Options after grant 26000.0000 Total derivative securities (options) beneficially owned after grant

Key Terms

restricted stock unit ("RSU") award, Share Option (right to buy), vests 25% on September 30, 2027

3 terms

restricted stock unit ("RSU") award financial

"Represents a restricted stock unit ("RSU") award. The RSUs vest 25% on September 30, 2027..."

Share Option (right to buy) financial

"security_title": "Share Option (right to buy)" for the derivative grant"

vests 25% on September 30, 2027 financial

"The RSUs vest 25% on September 30, 2027 and the remainder vests in 12 equal quarterly installments..."

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 07/30/2026 - 04:11 PM Accepted by SEC EDGAR 07/30/2026 - 04:11 PM Learn about SEC filing dates

FAQ

What equity awards did Compugen (CGEN) grant to CFO David Silberman?

Compugen granted CFO David Silberman 26,000 share options with an exercise price of 2.2600 and 19,500 restricted stock units (RSUs). Both awards were granted on July 29, 2026 as part of his executive compensation package.

What are the vesting terms of David Silberman’s RSUs at Compugen (CGEN)?

The 19,500 RSUs granted to David Silberman vest 25% on September 30, 2027. The remaining 75% vest in 12 equal quarterly installments thereafter, conditioned on his continued service to Compugen as stated in the award terms.

What are the key terms of the share options granted to Compugen (CGEN) CFO David Silberman?

Silberman received 26,000 share options with an exercise price of 2.2600 per share, expiring on July 29, 2036. These options vest 25% on September 30, 2027, with the balance vesting in 12 equal quarterly installments, subject to continued service.

How many Compugen (CGEN) ordinary shares does David Silberman hold after these grants?

After the July 29, 2026 RSU grant, David Silberman directly holds 55,000 ordinary shares of Compugen. In addition, he holds 26,000 options to acquire ordinary shares, reflecting his updated equity position reported in the Form 4 filing.

Were the Compugen (CGEN) Form 4 transactions market purchases or sales by the CFO?

The reported transactions are grants/awards, not open-market trades. Both the 19,500 RSUs and 26,000 options were acquired at a transaction price of 0.0000 per share, indicating issuer equity awards rather than purchases or sales in the market.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Silberman David

(Last) (First) (Middle)

C/O COMPUGEN LTD.

26 HAROKMIM STREET

(Street)

HOLON 5885849

(City) (State) (Zip)

ISRAEL

(Country)

2. Issuer Name and Ticker or Trading Symbol
COMPUGEN LTD [ CGEN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

2a. Foreign Trading Symbol
[CGEN]

3. Date of Earliest Transaction (Month/Day/Year)
07/29/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares	07/29/2026		A		19,500(1)	A	$0	55,000	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Share Option (right to buy)	$2.26	07/29/2026		A		26,000		(2)	07/29/2036	Ordinary Shares	26,000	$0	26,000	D

Explanation of Responses:

1. Represents a restricted stock unit ("RSU") award. The RSUs vest 25% on September 30, 2027, and the remainder vests in 12 equal quarterly installments thereafter, subject to the Reporting Person's continued service to the Issuer.

2. This option vests 25% on September 30, 2027 and the remainder vests in 12 equal quarterly installments thereafter, subject to the Reporting Person's continued service to the Issuer.

	/s/ David Silberman	07/30/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)